Subscribe
Healthcare

FDA approves drug to combat postpartum depression

By Cassidy Morrison
Published
Add Washington Examiner on Google
FDA approves drug to combat postpartum depression

The Food and Drug Administration approved the first drug designed specifically for postpartum depression treatment Tuesday.

Zulresso, Sage Therapeutics’ first product, is administered as an IV infusion by a professional in a certified healthcare facility. While the treatment lasts more than 60 hours, it reportedly starts working within days. Patients must be monitored during the treatment because of the risk of sedation or loss of consciousness.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

Family FDA Mental Health Pharmaceutical Industry